Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis
Authors:
Open Access
- 7 October 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 12
Abstract
Multidrug-resistant (MDR) isolates of Mycobacterium tuberculosis (MTB) remain a primary global threat to the end of tuberculosis (TB) era. Delamanid (DLM) is a nitro-dihydro-imidazooxazole derivative utilized to treat MDR-TB. DLM has distinct mechanism of action, inhibiting methoxy- and keto-mycolic acid (MA) synthesis through the F420 coenzyme mycobacteria system and generating nitrous oxide. While DLM resistance among MTB strains is uncommon, there are increasing reports in Asia and Europe, and such resistance will prolong the treatment courses of patients infected with MDR-TB. In this review, we address the antimycobacterial properties of DLM, report the global prevalence of DLM resistance, discuss the synergism of DLM with other anti-TB drugs, and evaluate the documented clinical trials to provide new insights into the clinical use of this antibiotic.Keywords
This publication has 92 references indexed in Scilit:
- Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosisEuropean Respiratory Journal, 2012
- Delamanid for Multidrug-Resistant Pulmonary TuberculosisNew England Journal of Medicine, 2012
- Substrate specificity of the deazaflavin‐dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazolesThe FEBS Journal, 2011
- Nitroimidazoles for the Treatment of TB: Past, Present and FutureFuture Medicinal Chemistry, 2011
- Synergistic Drug Combinations for Tuberculosis Therapy Identified by a Novel High-Throughput ScreenAntimicrobial Agents and Chemotherapy, 2011
- Metabolic Engineering of Cofactor F420 Production in Mycobacterium smegmatisPLOS ONE, 2010
- PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO ReleaseScience, 2008
- Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosisJournal of Antimicrobial Chemotherapy, 2007
- Synthesis and Antituberculosis Activity of a Novel Series of Optically Active 6-Nitro-2,3-dihydroimidazo[2,1-b]oxazolesJournal of Medicinal Chemistry, 2006
- OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In MicePLOS Medicine, 2006